Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Invivo CAR-T · 2 trials · 4 indications
MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment.
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.
MTD will be determined based on Dose-Limiting Toxicity (DLTs) observed during the first 28 days of study treatment.
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.
| Arm | Type | Description |
|---|---|---|
| Invivo CAR-T | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Invivo CAR-T | BIOLOGICAL | Patients were enrolled and given a single dose of CAR-T injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years. |
Inclusion Criteria: 1. Age ≥ 18 years old, gender unrestricted; 2. Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma; 3. ECOG performance status score 0-2, with an expected survival period of ≥ 3 months; 4. Blood routine...
Invivo CAR-T is an investigational cell therapy being developed for relapsed or refractory multiple myeloma (RRMM) and B-acute lymphoblastic leukemia. It is also being studied in B cell non-Hodgkin's lymphoma. The therapy is currently in Phase 1 clinical trials.
Invivo CAR-T is being developed by Precision BioSciences, Inc., a publicly traded company listed on NASDAQ under the ticker symbol DTIL. The company is conducting clinical trials for this investigational therapy in China.
Invivo CAR-T is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. Two Phase 1 trials are currently recruiting participants to evaluate the therapy's safety and efficacy.
Invivo CAR-T is being studied in two Phase 1 clinical trials. NCT07239323 is evaluating the therapy in relapsed or refractory hematological malignancies, including B-acute lymphoblastic leukemia, B cell non-Hodgkin's lymphoma, and multiple myeloma. NCT07715630 is specifically studying the therapy in relapsed or refractory multiple myeloma.
Invivo CAR-T is also referred to as In Vivo PICX CAR-T in clinical trial documentation. The trial NCT07715630, which is studying the therapy for relapsed or refractory multiple myeloma, uses the name In Vivo PICX CAR-T to describe the same investigational treatment.